The biosimilars market faces many challenges to development and uptake, resulting in uncertainty about the sustainability (long-term viability) of the market and concerns of future drug shortages, limited competition, and decreased innovation. In newly published work, Curta researchers outline a stakeholder-centered biosimilar market sustainability framework to inform research, shape policy agendas, and strategically address local, regional, and national decisions to align with long-term sustainability objectives.
The framework presented in this publication was created using a contemporary targeted literature review of the global biosimilars literature and a US-focused multistakeholder panel to identify key dimensions of biosimilar market sustainability and key stakeholder groups that impact and are impacted by the biosimilars market.
Key stakeholders include healthcare payers, regulatory/legal authorities, healthcare providers, patients, biologic manufacturers, and biologic purchasers. Dimensions incorporated into the framework include pricing and cost-savings, legal and regulatory barriers, manufacturer processes, provider choice, knowledge and preferences, and procurement processes. These dimensions are important considerations for stakeholders, and this framework can be used to engage stakeholders in identifying specific actions and policy changes to ensure long-term viability of the biosimilars market.